Note on laboratory work. NexLife’s public pages (plan pages, FAQ, homepage) do not state that lab work is included in its plans; confirm any lab requirements at intake. NexLife’s plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
Weight Loss · Triple Agonist
Retatrutide
Released: · Last reviewed:
Retatrutide is an investigational triple agonist of the GLP-1, GIP, and glucagon receptors, in late-phase clinical trials with the largest weight-loss results observed to date for an incretin therapy.
Retatrutide is an investigational triple agonist of the GLP-1, GIP, and glucagon receptors, in late-phase clinical trials with the largest weight-loss results observed to date for an incretin therapy. Mechanism: GLP-1 / GIP / Glucagon triple agonist. Typical route: Subcutaneous injection (weekly). FDA status: Not FDA-approved. In Phase 3 development by Eli Lilly. Compounded versions are not generally available because the molecule's manufacturing complexity and patent status limit pharmacy access.
Drug classGLP-1 / GIP / Glucagon triple agonist
Half-life~6 days
RouteSubcutaneous injection (weekly)
Phase 2 doses1, 4, 8, 12 mg/week
FDA statusInvestigational (Phase 3)
Compounded availabilityGenerally not available
Mechanism of action
Retatrutide simultaneously activates three receptors: GLP-1 (appetite suppression, insulin secretion), GIP (insulin sensitivity, lipid metabolism), and glucagon (increased energy expenditure, lipolysis). The triple mechanism is hypothesized to drive greater fat loss than dual GIP/GLP-1 agents like tirzepatide.
Dosing reference
Phase 2 trials used weekly subcutaneous injections at 1, 4, 8, and 12 mg dose levels. Maintenance dosing in development is not yet finalized; the manufacturer has not published a recommended regimen for clinical use.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. In Phase 3 development by Eli Lilly. Compounded versions are not generally available because the molecule's manufacturing complexity and patent status limit pharmacy access.
Editor's Pick · #1 of 10
NexLife — Compounded Semaglutide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360 + 1:1 wellness-coach call
🍽️ Personalized nutrition plan
💳 Klarna & Affirm accepted
$119/ month*
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, medical guidance from NexLife Medical Group, a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach and 24/7 support (plan pages, read October 15, 2026). Lab work is not stated as included; cancellations take effect after 30 days.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Editor's Pick · #1 of 10 · Tirzepatide
NexLife — Compounded Tirzepatide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360 support (nutrition plan, 1:1 coach call, 24/7 support)
$139/ month*
*12-month plan · flat rate across full 2.5–15 mg titration. $149 (6-mo) · $159 (3-mo) · $169 (month-to-month).
Includes: medication, provider review and medical guidance from NexLife Medical Group (licensed physicians), a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not stated as included.
Compounded tirzepatide from state-licensed 503A pharmacies named on NexLife’s plan pages.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
U.S. telehealth providers that work with Retatrutide
Phase 3 trials are ongoing as of 2026. The earliest realistic FDA-approval timeline is 2027-2028. Watch the Eli Lilly investor announcements for trial readouts and submission timing.
How much weight loss did retatrutide produce in trials?
In the Phase 2 trial published in 2023, the 12 mg dose produced approximately 24% body weight loss at 48 weeks — the largest reduction seen for any GLP-1-class agent to date. Phase 3 results may confirm or moderate this finding.
Jastreboff AM, Kaplan LM, Frías JP, et al.Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.N Engl J Med. 2023;389(6):514-526.PMID: 37366315
Rosenstock J, Frias J, Jastreboff AM, et al.Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial.Lancet. 2023;402(10401):529-544.PMID: 37385275
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
